CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05565417
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:11.839406+00:00
Published At: 2025-10-16T00:00:00+00:00
Record Updated At: 2025-10-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Cutaneous Squamous Cell Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Small Bowel Cancer", "Esophageal Cancer", "Colorectal Cancer", "Diffuse Large B Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Follicular Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-16"
protocolSection.identificationModule.nctId: "NCT05565417"
protocolSection.identificationModule.officialTitle: "A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.